Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
基本信息
- 批准号:10573196
- 负责人:
- 金额:$ 56.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:Angiogenesis InhibitorsBindingBioinformaticsBlood VesselsBreast Cancer ModelCCL2 geneCXCR4 geneCancer EtiologyCellsCessation of lifeCharacteristicsCommunicationDepositionDiseaseDisease ProgressionEndothelial CellsExtracellular MatrixFactor XIIIaFibrinFibrinolysisGeneticHeterogeneityHydrogelsImmuneInflammatoryKineticsLungLung AdenocarcinomaMediatingMicrofluidicsModelingMolecular ProbesMusNatureNeoplasm MetastasisOncogenesPlasminogen Activator Inhibitor 1RNA-Binding ProteinsRegulationReporterReportingRoleSignal TransductionSquamous Cell Lung CarcinomaStromal Cell-Derived Factor 1Transforming Growth Factor betaTumor AngiogenesisTumor Promotionangiogenesiscancer typecell motilityclinical investigationcrosslinkdensitydisorder controlextracellular vesicleshuman diseaseimmune checkpoint blockadeimprovedin vivoindexinginhibitorinsightmonocytemortalitymouse modelneoplastic cellnovelpharmacologicprogramsrecruitscaffoldsupport networktargeted treatmenttriple-negative invasive breast carcinomatumortumor growthtumor microenvironmenttumor progressionultrasoundvascular factorwound healing
项目摘要
Project Summary
Lung and triple-negative breast cancers (TNBCs) are leading causes of cancer-related deaths in the U.S. This
high mortality rate is largely due to their propensity to rapidly progress and metastasize. While targeted therapies
for lung adenocarcinoma have improved overall survival, similar advances in lung squamous carcinoma (LUSC)
and TNBC have been stagnant. However, for both cancer types, immune checkpoint blockade and/or
angiogenesis inhibitors improves disease control. Thus, a more complete understanding of how vascular/immune
niches within the tumor microenvironment (TME) promotes LUSC and TNBC will allow us to build upon these
advances. Our teams have recently demonstrated that LUSC and TNBC promote tumor growth and metastases
through a convergence on fibrin remodeling (Nature Communications, 2018; J Clinical Investigation, 2019) and
activation of endothelial cell wound-healing programs (Oncogene, 2019). Fibrin(ogen) that escapes leaky tumor
endothelial cells (TECs) acts as a scaffold for tumor cell motility and creates a provisional matrix for tumor
progression. Using highly integrated bioinformatics and novel LUSC models, we recently found that CCL2-
mediated recruitment of Factor XIIIA (FXIIIA)-expressing inflammatory monocytes (IMs) promotes fibrin cross-
linking, metastases and poor survival in LUSC. We also found that TEC heterogeneity (TECH) directs fibrin
accumulation through a TGFβ/miR-30c/PAI-1 signaling axis - TECs with high levels of the fibrinolysis inhibitor,
PAI-1, increase perivascular fibrin networks that support sprouting angiogenesis and tumor progression. We
have also uncovered a secondary connection between fibrin remodeling and the RNA-binding protein Quaking
(QKI) which is enriched in TECs and drives tumor angiogenesis. Silencing QKI in TECs inhibits sprouting
angiogenesis and metastases, but micro-vessel density (MVD) paradoxically increases; which we posit is due to
CXCL12-mediated sequestering of CXCR4+ IMs that initiate fibrin cross-linking. Based on these collective new
insights from our groups, we hypothesize that (i) inhibition of TEC QKI initially blocks tumor angiogenesis and
metastasis, however, a CXCL12-mediated retention of FXIIIA+ IMs promotes fibrin remodeling and rebound
angiogenesis. Additionally, we propose (ii) that TECH drives the formation of aberrant and persistent perivascular
fibrin scaffolds in LUSC and TNBC via a spectrum of TGFβ/miR-30c/PAI-1 expression. The objective of this
proposal is to elucidate how fibrin remodeling and tumor progression depend on the heterotypic relationships
between TECs and IMs, and the heterogeneity amongst TECs within the TME.
项目摘要
肺癌和三阴性乳腺癌(TNBCs)是美国癌症相关死亡的主要原因。
高死亡率在很大程度上是由于它们有快速进展和转移的倾向。虽然靶向治疗
肺腺癌提高了总体生存率,在肺鳞癌(LUSC)中也取得了类似的进展
和TNBC一直停滞不前。然而,对于这两种癌症,免疫检查点阻断和/或
血管生成抑制剂可改善疾病控制。因此,更全面地了解血管/免疫是如何
肿瘤微环境(TME)中的利基环境促进了LUSC,而TNBC将使我们能够在此基础上进一步发展
预付款。我们的团队最近证明了LUSC和TNBC促进肿瘤生长和转移
通过纤维蛋白重塑的趋同(《自然通讯》,2018;J临床研究,2019年)和
内皮细胞创伤修复程序的激活(致癌基因,2019)。纤维蛋白(原)能逃脱渗漏的肿瘤
血管内皮细胞(TECs)作为肿瘤细胞运动的支架,为肿瘤创造临时基质
进步。利用高度集成的生物信息学和新的LUSC模型,我们最近发现CCL2-
FXIIIA(FXIIIA)介导的表达炎性单核细胞(IMS)的募集促进纤维蛋白交叉
LUSC中的连接、转移和低存活率。我们还发现,TEC异质性(TECH)引导纤维蛋白
通过转化生长因子β/miR-30c/PAI-1信号轴-具有高水平纤溶抑制物的TECs积聚,
PAI-1,增加血管周围纤维蛋白网络,支持萌芽血管生成和肿瘤进展。我们
还发现了纤维蛋白重塑和RNA结合蛋白颤动之间的次要联系
(QKI),富含TECs,促进肿瘤血管生成。沉默TECs中的QKI抑制萌发
血管生成和转移,但微血管密度(MVD)矛盾地增加;我们认为这是由于
CXCL12介导的CXCR4+IMS的隔离启动纤维蛋白交联。基于这些集体新闻
根据我们小组的见解,我们假设(I)抑制TEC QKI最初会阻止肿瘤血管生成,并
然而,转移,CXCL12介导的FXIIIA+IMS滞留促进纤维蛋白重塑和反弹
血管生成。此外,我们提出(Ii)技术推动了异常的和持久的血管周围的形成
纤维蛋白支架通过转化生长因子β/miR-30c/PAI-1在喉癌和肿瘤细胞中的表达。这样做的目的是
建议阐明纤维蛋白重塑和肿瘤进展如何依赖于异型关系。
TEC和IMS之间的差异,以及TME内TEC之间的异质性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Carl Dudley其他文献
Andrew Carl Dudley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Carl Dudley', 18)}}的其他基金
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10356164 - 财政年份:2021
- 资助金额:
$ 56.85万 - 项目类别:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10179715 - 财政年份:2021
- 资助金额:
$ 56.85万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8693221 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8887312 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10399410 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10092966 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10621205 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
7708266 - 财政年份:2009
- 资助金额:
$ 56.85万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
8231654 - 财政年份:2009
- 资助金额:
$ 56.85万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Continuing Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Standard Grant
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Research Grant
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Fellowship
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Discovery Projects
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Discovery Projects